Nanopharmacology in translational hematology and oncology
Ciprian Tomuleasa,1,2,* Cornelia Braicu,1,* Alexandra Irimie,3 Lucian Craciun,1 Ioana Berindan-Neagoe1,4,51Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 2Department of Hematology, Ion Chiricuta Cancer Center, 3D...
Guardado en:
Autores principales: | Tomuleasa C, Braicu C, Irimie A, Craciun L, Berindan-Neagoe I |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8b29a25463494f839e77c0541e3570c6 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Combining the chemotherapeutic effects of epigallocatechin 3-gallate with siRNA-mediated p53 knock-down results in synergic pro-apoptotic effects
por: Berindan-Neagoe I, et al.
Publicado: (2012) -
MRI-based identification of undifferentiated cells: looking at the two faces of Janus
por: Tomuleasa C, et al.
Publicado: (2014) -
Sorafenib for the treatment of solid malignancies: what about the cancer microenvironment?
por: Tomuleasa C, et al.
Publicado: (2013) -
RNA interference: new mechanistic and biochemical insights with application in oral cancer therapy
por: Buduru S, et al.
Publicado: (2018) -
Future trends and emerging issues for nanodelivery systems in oral and oropharyngeal cancer
por: Irimie AI, et al.
Publicado: (2017)